Validations: Tech Transfer & Scale-Up Validation

Transfer Readiness Review (TRR): Templates and Evidence Required

Transfer Readiness Review (TRR): Templates and Evidence Required Transfer Readiness Review (TRR): Templates and Evidence Required Introduction to Transfer Readiness Review (TRR) The pharmaceutical industry is compelled to adhere to strict regulatory guidelines, particularly when transferring a product from one site to another or shifting a product from development to commercial manufacturing. The Transfer Readiness Review (TRR) serves as a…

Continue Reading Transfer Readiness Review (TRR): Templates and Evidence Required

Training & Qualification Program for Transferred Processes

Training & Qualification Program for Transferred Processes Training & Qualification Program for Transferred Processes Introduction to Transfer Validation In the pharmaceutical industry, process validation plays a crucial role in ensuring product quality and compliance with regulatory requirements. It is imperative to have a comprehensive training and qualification program when transferring processes from one facility to another or when scaling up…

Continue Reading Training & Qualification Program for Transferred Processes

Data Integrity in Equivalence Studies: Audit Trails and Part 11 Controls

Data Integrity in Equivalence Studies: Audit Trails and Part 11 Controls Data Integrity in Equivalence Studies: Audit Trails and Part 11 Controls The significance of data integrity in pharmaceutical equivalence studies cannot be understated. As regulations from organizations such as the FDA, EMA, and MHRA evolve to fortify data integrity principles, understanding the requirements for audit trails and adherence to…

Continue Reading Data Integrity in Equivalence Studies: Audit Trails and Part 11 Controls

Batch Definition and Lot Selection for Equivalence

Batch Definition and Lot Selection for Equivalence Batch Definition and Lot Selection for Equivalence Introduction In the pharmaceutical industry, ensuring consistency and reliability in product quality is paramount. This consistency is achieved through meticulous validation processes, particularly during tech transfer and scale-up operations. A critical aspect of this is the definition of batches and the selection of lots for equivalence…

Continue Reading Batch Definition and Lot Selection for Equivalence

DoE Bridging for Equivalence: CPP/CQA Mapping and Edge Selection

DoE Bridging for Equivalence: CPP/CQA Mapping and Edge Selection DoE Bridging for Equivalence: CPP/CQA Mapping and Edge Selection Introduction to DoE Bridging for Process Equivalence Process validation is a crucial aspect of pharmaceutical manufacturing and is governed by several regulatory frameworks, including the FDA regulations, EU GMP Annex 15, 21 CFR Part 11, and various international guidelines. A critical component…

Continue Reading DoE Bridging for Equivalence: CPP/CQA Mapping and Edge Selection

Assessing Method Robustness: ICH Q2(R2) and Q14 Hooks

Assessing Method Robustness: ICH Q2(R2) and Q14 Hooks Assessing Method Robustness: ICH Q2(R2) and Q14 Hooks In today’s pharmaceutical industry, ensuring the robustness of analytical methods is crucial for various types of testing, including bioanalytical methods. Adhering to international guidelines such as ICH Q2(R2) and ICH Q14 allows professionals to maintain compliance with regulatory requirements while ensuring data integrity throughout…

Continue Reading Assessing Method Robustness: ICH Q2(R2) and Q14 Hooks

Transfer Acceptance Limits: Bias, Precision, and Equivalence

Transfer Acceptance Limits: Bias, Precision, and Equivalence The process of analytical transfer in pharmaceutical development is critical for ensuring that methods remain robust and reliable across different laboratories and sites. In this tutorial, we will explore the concept of transfer acceptance limits in detail, focusing on bias, precision, and equivalence. Adhering to Good Manufacturing Practices (GMP) and regulatory guidelines from…

Continue Reading Transfer Acceptance Limits: Bias, Precision, and Equivalence

Biologics & ATMPs: CPV Considerations

Biologics & ATMPs: CPV Considerations Understanding Continued Process Verification in Biologics and ATMPs Continued Process Verification (CPV) is a crucial component in the lifecycle management of Biologics and Advanced Therapy Medicinal Products (ATMPs). It signifies an evolution from traditional quality assurance approaches to a more continuous and proactive methodology. Under the FDA, EU GMP Annex 15, and other regulatory frameworks,…

Continue Reading Biologics & ATMPs: CPV Considerations

Combination Products Post-Launch: CPV Tailoring

Combination Products Post-Launch: CPV Tailoring Combination Products Post-Launch: CPV Tailoring Introduction to Continued Process Verification (CPV) Combination products represent an essential segment of the pharmaceutical industry, merging drugs, devices, and biological products to improve therapeutic outcomes. As these products transition from the development phase to post-launch activities, a comprehensive approach to continued process verification (CPV) is critical. CPV not only…

Continue Reading Combination Products Post-Launch: CPV Tailoring

Parametric Release Environments: CPV Hooks

Parametric Release Environments: CPV Hooks Parametric Release Environments: CPV Hooks Introduction to Parametric Release and Continued Process Verification (CPV) In the pharmaceutical industry, ensuring product quality throughout the lifecycle is paramount. As regulatory expectations evolve, continued process verification (CPV) is becoming an increasingly important element of the overall validation framework. CPV not only helps in maintaining compliance with standards such…

Continue Reading Parametric Release Environments: CPV Hooks